HIV-Negative Plasmablastic Lymphoma: Not in the Mouth

Castillo, Jorge J.; Winer, Eric S.; Stachurski, Dariusz; Perez, Kimberly; Jabbour, Melhem; Milani, Cannon; Colvin, Gerald A.; Butera, James N.

doi:10.1016/j.clml.2011.03.008

Cited by 84 publications

(87 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a recent review of literature, patients with PBL and HIV infection were found to have an OS of 14 months compared to 9 months in HIV-negative patients [36]. A review of 112 HIV positive patients with PBL showed a median overall survival (OS) of 15 months and a 3-year OS rate of 25 % [12], compared to a review of 76 HIV-negative PBL patients that showed a median OS of 9 months with a 2-year OS rate of 10 % [40].…”

Section: Cytogenetic Analysismentioning

confidence: 99%

Clinicopathologic features of plasmablastic lymphoma: Single-center series of 8 cases from Saudi Arabia

et al. 2015

View full text Add to dashboard Cite

Background: Plasmablastic lymphoma (PBL) is a rare subtype of non-Hodgkin's lymphoma. Characterized by its aggressive nature and plasmacytic differentiation, PBL remains a therapeutic and diagnostic challenge; it generally has a poor prognosis with very few long-term survivors and most patients dying within 2 years from initial presentation. PBL has been reported in several other countries; however, there have been no reported cases from Saudi Arabia. Here, we report 8 cases of PBL depicting the clinical presentation, immunocompetency, immunphenotypic characterization, diagnostic challenges and treatment outcome. Methods: The medical records were reviewed for clinical presentation, staging, laboratory data, radiological studies, treatments, and outcomes. A broad immunohistochemical panel consisting of CD45, CD3, CD20, CD79a, Pax5, CD38, CD138, MUM1, EMA, Kappa, Lambda, CD 56, CD30, Bcl-2, Bcl-6, Alk-1, Ki-67, EBV-LMP-1, and HHV8 was performed. Results: The tumors predominantly exhibited immunoblastic/plasmablastic or plasmacytic morphologic features and had a plasma cell-like immunophenotype. All cases were immunoreactive for CD38, CD138 and MUM1 confirming plasma cell differentiation of the tumor cells. CD20 was negative for all cases; whereas CD79a and Pax5 were weakly positive in 2cases. All 8 cases were EBV-LMP-1/EBER-1 negative, and 1 case was HHV8 positive. Similar to previously published studies, PBL in Saudi Arabia is characterized by male predominance (6/8), median age 51.5 years (mean age 46 years), associated with early dissemination, poor response to therapy, and limited survival (average survival time, 6.4 months, median overall survival 5.5 months). However, it does have some unique features. It occurs more commonly in immunocompetent persons (6/8, 75 %), is not associated with EBV infection (0/8), and nodal involvement (either primary or secondary) is common among patients (6/8). In addition, extra-oral sites are more common than oral/nasal cavities (7/8) and the c-myc gene is not common (1/8, 12.5 %).

show abstract

Section: Cytogenetic Analysismentioning

confidence: 99%

Clinicopathologic features of plasmablastic lymphoma: Single-center series of 8 cases from Saudi Arabia

et al. 2015

View full text Add to dashboard Cite

show abstract

“…3 The expression of CD20 or CD45 has not been associated with outcomes in patients with PBL. 39,42,44 Conversely, a series of studies have suggested a worse outcome in patients with Ki-67 expression .80%. 3,39,42,44 A smaller study did not show prognostic value for Ki-67 expression.…”

Section: Survival and Prognostic Factorsmentioning

confidence: 99%

“…39,42,44 Conversely, a series of studies have suggested a worse outcome in patients with Ki-67 expression .80%. 3,39,42,44 A smaller study did not show prognostic value for Ki-67 expression. 6 In HIV-associated PBL, CD4 1 counts ,0.2 3 10 9 /L were not associated with worse OS 3,41 but appeared to associate with shorter progression-free survival time.…”

Section: Survival and Prognostic Factorsmentioning

confidence: 99%

“…38 Similarly, a systematic review of 76 HIV-negative PBL patients showed a median OS of 9 months with a 2-year OS rate of 10%. 39 A more recent systematic review of approximately 300 patients with PBL showed a median OS of 8 months. The median OS in HIV-positive patients was 10 months, 11 months in HIV-negative immunocompetent, and 7 months in posttransplant PBL patients.…”

Section: Survival and Prognostic Factorsmentioning

confidence: 99%

See 1 more Smart Citation

The biology and treatment of plasmablastic lymphoma

Castillo

Bibas

Miranda

2015

Blood

Self Cite

355

524

View full text Add to dashboard Cite

Plasmablastic lymphoma (PBL) is an aggressive lymphoma commonly associated with HIV infection. However, PBL can also be seen in patients with other immunodeficiencies as well as in immunocompetent individuals. Because of its distinct clinical and pathological features, such as lack of expression of CD20, plasmablastic morphology, and clinical course characterized by early relapses and subsequent chemotherapy resistance, PBL can represent a diagnostic and therapeutic challenge for pathologists and clinicians alike. Despite the recent advances in the therapy of HIV-associated and aggressive lymphomas, patients with PBL for the most part have poor outcomes. The objectives of this review are to summarize the current knowledge on the epidemiology, biology, clinical and pathological characteristics, differential diagnosis, therapy, prognostic factors, outcomes, and potential novel therapeutic approaches in patients with PBL and also to increase the awareness toward PBL in the medical community.

show abstract

“…HIV-negative patients tend to have an older age at presentation and a worse prognosis compared to HIV-positive patients. Within the smaller subset of HIV-negative patients, there are even more rare associations such as Epstein-Barr virus infection and other immunecompromised states such as solid organ transplantation and immunosenescence secondary to advanced age [2,3,4]. It also can occur in many anatomic sites, ranging from classic nodal sites to extra nodal sites, such as the gastrointestinal tract, soft tissues, and…”

Section: Introductionmentioning

confidence: 99%